Human IL-36 beta/IL-1F8 (aa 5-157)組換え体(リコンビナント)タンパク質 | Recombinant Human IL-36 beta/IL-1F8 (aa 5-157)

R&D Systems社製の高品質なHuman IL-36 beta/IL-1F8 (aa 5-157)の組換え体タンパク質(Recombinant Human IL-36 beta/IL-1F8 (aa 5-157))です。

※本製品は研究用です。研究用以外には使用できません。

※バルク包装品も承ります。お気軽にお問合せ下さい。

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

Interleukin-36 beta (IL-36 beta, previously known as IL-1F8, FIL-1 eta (eta) and IL-1H2, is a member of the IL-1 family of proteins that also includes IL-1 beta, IL-1 alpha, IL-1ra,
IL-18, IL-36Ra/IL-1F5, IL-36 alpha /IL-1F6, IL-37/IL-1F7, IL-36 gamma /IL-1F9, and IL-1F10 (1, 2). IL-1 family cytokines are characterized by a 12  beta -stranded beta -trefoil configuration and share up to 50% amino acid (aa) sequence identity. The 157 aa human IL-36 beta does not have a canonical signal peptide or prosegment and is expressed as two isoforms that differ in their C-terminal 70 aa. IL-36 beta 1 lacks four of the conserved beta -strands common to the IL-1 family (3). Human IL-36 beta 2 shares 62%, 67%, 63% and 59% aa identity with the most similar isoforms of mouse, canine, bovine and equine IL-36 beta, respectively (4). IL-36 beta is expressed by keratinocytes, naïve CD4⁺ T cells, neurons, and glia (5-7). It is up-regulated in keratinocytes and synovial fibroblasts by inflammatory stimulation and in psoriatic lesions (5, 8, 9). IL-36 beta promotes inflammatory responses by enhancing the activation and Th1 polarization of dendritic cells and T cells (7, 10, 11). It also enhances the production of multiple pro-inflammatory cytokines, chemokines, and anti-bacterial defensin peptides by keratinocytes, synovial fibroblasts, and articular chondrocytes (5, 8-10). IL-36 proteins exert their bioactivity through a receptor complex that contains IL-1 Rrp2 and IL-1 RAcP, and this is antagonized by IL-36Ra which also binds IL-1 Rrp2 (11, 12). The potency of IL-36 beta is increased by cleavage of its first four N-terminal amino acids (13).